Patients with type 2 diabetes should be offered SGLT-2 inhibitors, known as ‘flozins’, much earlier in their treatment, according to updated guidelines.
The post NICE backs early use of flozins in ‘landmark moment for diabetes care’ appeared first on Nursing Times.